{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.","slug":"derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d","published_at":"2026-06-01T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19248045-derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19248045-derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He al...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2992,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}